Showing 4581-4590 of 5771 results for "".
- Bausch + Lomb Launches Infuse Silicone Hydrogel (SIHY) Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-infuse-silicone-hydrogel-sihy-daily-disposable-contact-lenses/2478170/Bausch + Lomb announced the launch of Bausch + Lomb Infuse silicone hydrogel (SiHy) daily disposable contact lens. The Infuse lenses feature a next generation material infused with ProBalance Technology to help maintain ocular surface homeostasis and help reduce symptoms of contact lens dryness,
- Sanofi Enters $3.7-Billion Deal to Buy Principia Biopharmahttps://modernod.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/Sanofi announced Monday a definitive agreement to acquire all of Principia Biopharma’s outstanding stock for $100 per share in cash, representing an equity value of around $3.7 billion, boosting the French drugmaker’s core research areas of autoimmune and allergic diseases. The deal,
- Contact Lens Institute Will Launch Health & Safety Program this Fallhttps://modernod.com/news/contact-lens-institute-will-launch-health-safety-program-this-fall/2478167/The Contact Lens Institute (CLI) announced that it will launch a sustained initiative this fall to promote healthy contact lens wear and care habits, in conjunction with US eye care professionals (ECPs). This comes as the U.S. Centers for Disease Control and Prevention’s seventh annual Contact Le
- FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/fda-approves-genentechs-enspryng-for-neuromyelitis-optica-spectrum-disorder/2478165/Genentech announced that the FDA has approved Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, li
- Avellino Hits 1-Million Genetic Test Milestonehttps://modernod.com/news/avellino-hits-1-million-genetic-test-milestone/2478164/Avellino announced that the company has performed over 1-million genetic and molecular diagnostic tests. This milestone includes over 821,000 universal tests for TGFBI corneal dystrophy, over 180,000 AvellinoSARS-CoV-2/COVID-19 (AvellinoCoV2) tests since March 2020, and the November 2019 launch o
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- Gyroscope Therapeutics Initiates Phase 2 Program Evaluating its Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-initiates-phase-2-program-evaluating-its-investigational-gene-therapy-for-dry-amd/2478157/Gyroscope Therapeutics announced the initiation of its phase 2 program evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is a one-time AAV-based gene therapy that is delivered under the r
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance for Pipeline Therapieshttps://modernod.com/news/agtc-formalizes-patient-advisory-council-to-provide-insights-and-guidance-for-pipeline-therapies/2478156/Applied Genetic Technologies Corporation (AGTC), announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the company’s culture and clinical and preclinical programs. Engagement with pa